Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More
you are here: HomeNewsIndia

COVID-19: CSIR lab develops technology to meet oxygen demand, minimise storage risks

This will help the accessibility of oxygen in remotest places and widest points of need. The outreach factor of oxygen will be multiplied through the adoption of this in-situ and decentralised generation of oxygen, Hirani said.

April 22, 2021 / 10:08 PM IST
Image courtesy: PIB India

Image courtesy: PIB India

The CSIR on Thursday said an oxygen enrichment technology has been developed by one of its laboratories to meet the oxygen demand and minimise the supply chain problem of transportation and storage risks related to oxygen cylinders amid the COVID-19 outbreak.

The Council of Scientific and Industrial Research's (CSIR) Central Mechanical Engineering Research Institute (CMERI) has transferred the technology virtually to M/s Apollo Computing Laboratories (P) Ltd, Kushaiguda, Hyderabad.

As the nation grapples with the surge of coronavirus cases, oxygen therapy is recommended for severe illness caused by the infection. At the same time, several states have reported acute shortage of medical grade oxygen.

Talking about the technology, Professor Harish Hirani, director, CSIR-CMERI, said the unit requires easily available oil free reciprocating compressor, oxygen grade zeolite sieves and pneumatic components.

It is capable of delivering medical air in the range of up to 15 LPM (litre per minute) with oxygen purity of more than 90 per cent. If required, this unit can even deliver up to 70 LPM at a purity of around 30 per cent and can safely be placed in the isolation ward of hospitals for patients who are in dire need of oxygen, he said.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

This will help the accessibility of oxygen in remotest places and widest points of need. The outreach factor of oxygen will be multiplied through the adoption of this in-situ and decentralised generation of oxygen, Hirani said.

He said further research is going on to develop a pulse dose mode which is capable of sensing the breathing pattern of a patient and then deliver during inhalation only.

This mode is supposed to reduce the oxygen demand by around 50 per cent when compared with the current version of continuous mode, the professor added.

The CSIR-CMERI has already invited Expression of Interest (EOI) from Indian companies, manufacturing agencies, MSMEs or start-ups for manufacturing Oxygen Enrichment Units through Technology Transfer.

Jaipal Reddy of M/s Apollo Computing Laboratories said the first prototype will be developed within 10 days and the production will start from the second week of May.

They have presently the manufacturing capacity of 300 units per day which may be augmented on demand, he said.

Reddy said their company is planning to develop the unit both as standalone as 'Oxygen Enrichment Unit' as well as with integrated version with 'Swasth Vayu' technology of CSIR-National Aerospace Laboratories.

He stressed that the unit is essentially required as mini ICUs at small hospitals and isolation centres and at remote villages and places.

By the use of oxygen concentrators, the optimum utilisation of oxygen to needy patients may also be ensured.

If this facility is provided to COVID-19 patients at initial stage, their visits to hospitals and further ventilator support may be avoided in most of the cases, the CSIR said.

Follow our full coverage of the coronavirus pandemic here.

stay updated

Get Daily News on your Browser